Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
CTContineum Therapeutics, Inc. logo

Contineum Therapeutics, Inc. (CTNM)

NASDAQ · Currency in USD
$8.31 ▼ -0.09 (-1.01%)
At close: Oct 23, 4:00 PM ET. Market closed.
$8.24 ▼ -0.07 (-0.82%)
After hours: Oct 23, 5:31 PM ET

Summary

Previous Close
$8.40
Open
$8.24
Day's Range
$8.01 – $8.41
52 Week Range
$6.73 – $17.79
Volume
428,769
Avg. Volume
704,732
Market Cap
$273.89M
Beta (5Y Monthly)
0.75
PE Ratio (TTM)
--
EPS (TTM)
-$1.54
Earnings Date
Oct 29, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$21.33

Profile: Contineum Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
51
CEO
Carmine N. Stengone

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis.

Earnings

Next report: Thu, Oct 29, 2026
EPS estimate -$0.45 · Revenue est. $5.65M
DateEst.Actual
Jul 30, 2026-$0.45-$0.40Beat
May 5, 2026-$0.55-$0.39Beat
Mar 5, 2026-$0.50-$0.49Beat
Oct 30, 2025-$0.58-$0.45Beat
Aug 5, 2025-$0.56-$0.62Miss
May 14, 2025-$0.56-$0.62Miss

Analyst view

Consensus price target
$21.33 ▲ +156.7%
Range $17.00 – $28.00
Rating: Buy
Buy 50% · Hold 50% · Sell 0%

Get free alerts on CTNM and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.